June 17, 2021 -- Mobilion Systems has launched a high-resolution ion mobility (HRIM) mass spectrometry instrument called Mobie for biopharmaceutical drug development and workflows for monitoring critical quality attributes.
The new product is based on structures for lossless ion manipulation (SLIM) technology, which extends the ion mobility path beyond other devices, thereby producing more extensive separations to reveal previously undetectable molecules, according to the company. The separations technology addresses characterization challenges that scientists face during biopharmaceutical drug development and quality monitoring, the company said.
The firm's SLIM technology allows scientists to separate and identify molecular structures that would either be too time-consuming or difficult to detect with methods like liquid chromatography. Mobie can be used to analyze a variety of analyte classes including peptides, proteins, lipids, and glycans between five to 60 times faster than conventional separation methods.
SLIM technology was invented by Dr. Richard Smith of Pacific Northwest National Laboratory with the goal of untangling the complexities of analyte classes for biomarker discovery, enabling a greater level of characterization.
In 2018, Mobilion announced a partnership with Agilent Technologies to integrate its first HRIM system with Agilent's 6500 line of quadrupole time-of-flight (Q-TOF) mass spectrometers. The combination of technologies produces more extensive separations to reveal previously undetectable molecules. Together, the technologies provide a tool to help pharmaceutical companies develop safer and more effective biologic therapeutics and help academic researchers discover novel biomarkers, according to the firms.
Earlier this year, Mobilion and Protein Metrics announced the integration of Protein Metric's Byos biopharma software suite with Mobilion's SLIM product. The partnership delivers a full workflow solution with fast, easy data processing, according to the company.